Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Liabilities and Shareholders Equity (2021 - 2025)

Bioregenx's Liabilities and Shareholders Equity history spans 5 years, with the latest figure at $410986.0 for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $410986.0 for Q4 2025, down 19.18% from a year ago — trailing twelve months through Dec 2025 was $3.2 million (down 94.09% YoY), and the annual figure for FY2025 was $410986.0, down 19.18%.
  • Liabilities and Shareholders Equity for Q4 2025 was $410986.0 at Bioregenx, down from $1.2 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $18.6 million in Q1 2024 to a low of $33981.0 in Q3 2023.
  • The 5-year median for Liabilities and Shareholders Equity is $495579.0 (2024), against an average of $4.2 million.
  • The sharpest move saw Liabilities and Shareholders Equity soared 50991.39% in 2024, then plummeted 97.41% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $127762.0 in 2021, then crashed by 53.7% to $59149.0 in 2022, then skyrocketed by 1363.68% to $865750.0 in 2023, then tumbled by 41.26% to $508535.0 in 2024, then decreased by 19.18% to $410986.0 in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $410986.0, $1.2 million, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.